Archives

Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis

B WILMINGTON, Del., April 2, 2026 /PRNewswire/ — Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in… Login to continue reading Login…

Read MoreEarendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis

WindRose Health Investors Launches WindRose Gradient, a Dedicated Technology Services Team to Support Portfolio Company AI Capabilities

B NEW YORK, April 2, 2026 /PRNewswire/ — WindRose Health Investors, LLC (“WindRose”), the New York-based healthcare private equity firm, announced that it has established… Login to continue reading Login…

Read MoreWindRose Health Investors Launches WindRose Gradient, a Dedicated Technology Services Team to Support Portfolio Company AI Capabilities